



Vaccines, a healthy future

Developing Countries Vaccines Manufacturers Network

Speakers' Book

21st Annual General Meeting

November 3rd - 5th, 2020

Virtual platform

DAY 1,
3rd November 2020 | 11:00 a.m -14:00 CET
Partners Forum - for all participants

	<p>Chair: Mr. Tan Chin Bin <i>Head of the Technology Management and MSAT organization of Asia Pacific for Merck Life Science, Process Solutions</i></p> <p>His organization drives technical and product knowledge to the pharmaceutical, and routinely delivers high level technical expertise to pharmaceutical companies, industrial associations, institutes and government linked programs. Graduated from National University of Singapore in Chemical Engineering, and with more than 15 years' experience in the Biopharmaceutical Industry across Asia.</p>
	<p>Chair: Dr. Ted Prusik <i>Co-founder and Senior Vice President, Temptime</i></p> <p>Dr. Prusik's inventions helped create Temptime's technology which helps global health organizations monitor the temperature of vaccines and other biologics to prevent administration of vaccines compromised by high levels of heat or cold. He holds a PhD in chemical physics from New York University. Temptime is now part of Zebra Technologies.</p>
	<p>Co-Chair: Dr. Mats Lundgren <i>Director, GE Healthcare Life Sciences</i></p> <p>Dr. Lundgren has more than 25 years of experience in vaccinology. As Customer Applications Director at GE, he helps companies implement modern processes with the goal of achieving more efficient production and higher vaccine quality.</p>
	<p>Moderator: Mr. Benoit Hayman <i>Research Associate, DCVMN</i></p> <p>Mr. Hayman is a Research Associate at DCVMN International where he supports Network memberships and partnerships. He conducts member surveys and data analysis, focusing on innovative technologies in addition to contributing online training tools. He is currently studying a Master of Science degree in economics at the University of Lausanne.</p>

	<p>Dr. Ted Prusik <i>Co-founder and Senior Vice President, Temptime</i></p> <p>Dr. Prusik's inventions helped create Temptime's technology which helps global health organizations monitor the temperature of vaccines and other biologics to prevent administration of vaccines compromised by high levels of heat or cold. He holds a PhD in chemical physics from New York University. Temptime is now part of Zebra Technologies.</p>
	<p>Ms. Josephine Cheng <i>Associate Director Vaccines & Plasma, APAC, Merck</i></p> <p>Josephine is responsible for plasma & Vaccine segments development; looking closely into customer needs, market insights, and facilitating innovative collaboration projects. She has over ten years pharmaceutical industry experience in marketing, customer training, and technical support, with background skills in biotechnology. She holds a MSc in Phytochemical laboratory from the National Taiwan University.</p>
	<p>Dr. Mats Lundgren <i>Customer Applications Director, Cytiva</i></p> <p>Dr. Lundgren has more than 25 years of experience in vaccinology. As Customer Applications Director at GE, he helps companies implement modern processes with the goal of achieving more efficient production and higher vaccine quality.</p>
	<p>Mr. Tim Kram <i>General Manager, Rommelag, USA</i></p> <p>Mr. Kram is an Engineer and pharmaceutical business development professional. For the past 16 years, he has worked with companies to develop aseptic product fill/finish solutions using Blow/Fill/Seal technology. For ten years he has worked to introduce temperature sensitive biotech and vaccine products to BFS technology.</p>
	<p>Mr. Tony Xu <i>Business Development Manager, Tofflon</i></p> <p>He has over 10 years of experience in Biopharma and Pharma Equipment application. His expertise includes professional project management of all types of pharmaceutical machines/integrate system/New Facility Engineering and Biopharma Fermenter/Chromatography/ Filtration/Solution preparation) Bulk line + Fill & Finish line. He is leading the business development team to achieve the goals according to Tofflon's overseas strategies.</p>



Dr. Vibin Joseph
Executive Director, Biozeen

Vibin steers the strategic direction at Biozeen. He leads geographic expansion, business model evolution and process optimizations. He is an engineer with a major in mechanical and management degree from Imperial College London, and doctoral research from Warwick University. His research interests lie in systems design, design psychology and moderating influencers in the pharmaceutical industry.



Ms. Anaita Daruvala
Head of Business development, Bioengineering

Bioengineering AG has engineered and manufactured research-scale to production bioreactor systems for human and veterinary vaccines for manufacturers in developing nations since 1972.



Dr. Markus Kühberger
Director Business Line Chemical & Pharma, GEA Westfalia Separator Group

Dr. Kühberger is a graduate engineer specializing in industrial engineering - technical chemistry at the Johannes Kepler University Linz, Austria. Working for GEA since 2006; from 2019 as director of the business line Chemical & Pharma in Germany which is specialized in the development of centrifuge systems for biopharmaceutical downstream processing, e.g. vaccine production.

DAY 2,

**4th November 2020 | 11:00 a.m -14:00 CET
 Plenary Opening Session - for all participants**

	<p>Chair: Mr. Sai Prasad <i>President, Quality Operations, Bharat Biotech</i></p> <p>Mr. Prasad oversees all aspects of quality management to provide global access to innovative vaccines and biologics, manufactured at scale. His working expertise from USA and Asia, are focused on product development, media relations, contract negotiations, advocacy, mergers & acquisitions, funding raising, project proposals, human resources management, technical operations, etc.</p>
	<p>Co-chair: Mrs. Lingjiang Yang <i>Manager of International Business and Cooperation, Chengdu Institute of Biological Products Co., Ltd. (CDIBP), CNBG</i></p> <p>Mrs. Yang is responsible for all international cooperation development and management as well as international marketing. Her experience as the project coordinator of the WHO prequalification of live Japanese Encephalitis vaccine has given her insight into the global vaccine industry.</p>
	<p>Moderator: Dr. Maureen Dennehey <i>Project Manager, DCVMN</i></p> <p>Dr. Dennehey is a consultant to pharmaceutical, biologicals and medical device manufacturers in Operations and Quality. She has worked with DCVMN since 2015 and previously established the Quality functions at Biovac, South Africa. She has a PhD and MBA, is an IRCA-certified auditor and ISPE Certified Pharmaceutical Industry Professional (CPIP).</p>
	<p>Dr. Tedros A. Ghebreyesus <i>WHO Director-General</i></p> <p>A globally recognized health scholar, researcher, and diplomat, Dr. Tedros was elected WHO Director-General in 2017. Immediately after taking office, Dr. Tedros outlined five key priorities for the Organization: universal health coverage; health emergencies; women's, children's and adolescents' health; health impacts of climate and environmental change; and a transformed WHO.</p>

	<p>Dr. Bruce Aylward <i>Senior Advisor to the Director-General/WHO & Head of the ACT-Accelerator (Hub)</i></p> <p>Dr. Aylward has led the design and implementation of WHO's Transformation Agenda since September 2017 and since June 2020 has led the multi-agency Access to COVID-19 Tools Accelerator (ACT-A) hub. In February 2020 he led the WHO-China Joint Mission on Coronavirus Disease 2019 (COVID-19). He has served WHO in a variety of leadership positions in the areas of emergencies, disease eradication, and vaccines and immunization.</p>
	<p>Dr. Seth Berkley <i>CEO, Gavi, the Vaccine Alliance</i></p> <p>Dr. Berkley is a medical doctor and infectious disease epidemiologist and joined Gavi, as its CEO in August 2011, spearheading its mission to protect the world's poorest children by improving access to new and underused vaccines. Dr Berkley is co-leading the Vaccines Pillar of the Access to COVID-19 Tools (ACT) Accelerator, working to develop and distribute a SARS-CoV-2 vaccine globally.</p>
	<p>Dr. Richard Hatchett <i>CEO, CEPI (Coalition for Epidemic Preparedness Innovations)</i></p> <p>Dr. Hatchett has led medical countermeasure development programs at BARDA and the U.S. NIH. He has played leading roles at HHS and the White House in designing these programs as well as in planning for and responding to H5N1 avian influenza, the 2009 H1N1 influenza pandemic, Ebola, MERS, and Zika epidemics.</p>
	<p>Ms. Etleva Kadilli <i>Director, UNICEF Supply Division</i></p> <p>Ms. Kadilli is Director of UNICEF's Supply Division in Copenhagen, Denmark, overseeing UNICEF's global supply operations in development and emergency contexts, with an annual expenditure exceeding USD 3.8 billion. An Albanian national, Ms. Kadilli has worked for UNICEF nearly 25 years in various supply and programme operations roles.</p>
	<p>Ms. Marion Menozzi-Arnaud <i>Senior Projects Specialist, Market Shaping Team, Gavi, the Vaccine Alliance</i></p> <p>Ms. Menozzi-Arnaud works on strategic cross portfolio projects where she contributes to the identification of solutions for broad questions arising from market-based health commodity related challenges. Previously, she was Head of Pricing and Market Access, Biosimilars at Merck, and before that she spent 15+ years working as a management consultant.</p>

	<p>Dr. Birgitte Giersing <i>Team Lead, Vaccine Product and Delivery Research, Department of Immunizations, Vaccines and Biologics (IVB), WHO</i></p> <p>Dr. Giersing is the Secretariat for IVB's Product Development Vaccine Advisory Committee (PDVAC) and focuses on vaccine product and delivery research for priority vaccines. She previously led vaccine development programmes in private industry, and prior that worked in malaria vaccine development at PATH and NIH.</p>
	<p>Dr. Robin Shattock <i>Head of Mucosal Infection and Immunity, Department of Medicine, Imperial College London</i></p> <p>Dr. Shattock's research focuses on the mechanisms of mucosal infection and the development of novel preventative strategies appropriate to a developing world setting. He oversees a portfolio of research that is supported by 26 members of staff and has published over 160 peer reviewed articles in this area.</p>
	<p>Mr. Arnaud Bernaert <i>Head of Shaping the Future of Health and Healthcare, World Economic Forum</i></p> <p>As a member of the Executive Committee and the Health of Healthcare at the World Economic Forum, Arnaud Bernaert has launched defining public private coalitions in fields such as epidemics preparedness, value-based healthcare, precision medicine, access to primary care, payment reforms, healthcare IT; participating as a keynote speaker in the most prestigious global healthcare gatherings.</p>
	<p>Mr. Chand Mehta <i>Programme manager, Vaccine Market Shaping Team, Clinton Health Access Initiative (CHAI).</i></p> <p>Chand leads CHAI's vaccine strategy with Indian suppliers and supports Gavi Partners on supply sustainability. He has specific focus on rotavirus and typhoid vaccines; and leads CHAI's COVID-19 vaccine manufacturing response. Previously, Chand was a business analyst at Novartis and received his BA Hons and MSc from Oxford University.</p>
	<p>Ms. Beth Evans <i>Program manager, Global Vaccines, Clinton Health Access Initiative (CHAI).</i></p> <p>Beth leads the team's work on vaccine innovation and epidemic preparedness – engaging with developers and global health partners to accelerate development of and access to high-impact novel antigen vaccines. She holds a BA from Cambridge University in Natural Sciences (Biological) and worked briefly at the Centre for Pathogen Evolution on influenza vaccine research post-graduation.</p>



Mr. Nikolaj Gilbert
President and CEO, PATH

Nikolaj Gilbert is president and chief executive officer of PATH. He brings more than 20 years of international experience as a leader, strategist, and director of complex partnerships. With a proven track record in both the private and public sectors, his expertise spans health, peacebuilding, humanitarian aid, and development solutions.



Dr. Jarbas Barbosa Da Silva Jr.
Assistant Director, PAHO

Dr. Jarbas Barbosa, has served as PAHO Assistant Director since 2018. He joined PAHO for the first time in 2007 as the Area Manager, Health Surveillance and Disease Management until his return to Brazil in 2010. Prior to his current position, he served as the Director-President of the Brazilian Health Regulatory Agency.



Dr. Anita Zaidi
Director of the Vaccine Development, Surveillance, and Enteric and Diarrheal Diseases programs, Bill & Melinda Gates Foundation

Focused on vaccine development for people in the poorest parts of the world. Prior to joining the foundation, Anita was the Ruby and Karim Bahudar Ali Jessani Professor and chair, Department of Pediatrics and Child Health, at the Aga Khan University. Anita obtained her medical degree from the Aga Khan University in Karachi.

DAY 3,
5th November 2020 | 11:00 a.m -14:00 CET
Plenary Session - for all participants



Chair: Mr. Fernando Lobos
Business Development Director, Sinergium Biotech SA.

Mr. Lobos, Engineer and MBA, with 20-years' experience in management, focused on new business development, engineering, start-up and operations of pharmaceutical companies. Previous experience includes positions as Operations Manager, Latin America Supply Chain Manager, Production Manager and Engineering Manager in top multinational companies starting in 1995.



Co-Chair: Ms. Rachel Park
General Manager, Eubiologics

Rachel Park has been with EuBiologics from prequalification to commercialization of Euvichol-Plus, oral cholera vaccine since 2015. She's a director in business development division at EuBiologics, responsible for marketing, business development of its pipeline products and collaboration with international stakeholders.



Moderator: Mr. Stephen Jarrett
Independent consultant

Stephen Jarrett, with a background in engineering and public health, has been associated with UNICEF since 1972 as staff and consultant, supporting China's immunization coverage acceleration in the 1980s and overseeing UNICEF Supply Division's evolution in vaccine procurement since the late 1990s. He is currently helping DCVMN with supply chain issues.



Dr. Jerome Kim
Director General, International Vaccine Institute (IVI)

Jerome Kim, M.D., is an international expert on the evaluation and development of vaccines. His depth and breadth of scientific experience spans basic research through advanced clinical development. He is a graduate of the University of Hawaii, with high honors in History and Biology, and received his M.D. from Yale University School of Medicine.

	<p>Dr. Sarah Gilbert <i>Professor of Vaccinology, Oxford University/VaxHub</i></p> <p>Professor Gilbert's chief research interest is the development of viral vectored vaccines that work by inducing strong and protective T and B cell responses. She is a co-founder of Vaccitech and now also works on vaccines for many different emerging pathogens, including Nipah, MERS, Lassa and CCHF.</p>
	<p>Dr. Melanie Saville <i>Head of Vaccine R&D, CEPI</i></p> <p>Dr. Saville leads a technical team who have oversight of the CEPI funded vaccines in development. Melanie is a physician specialized in virology with 20 years of experience in the development and licensure of vaccines for the developed and developing world. Over the years, she has contributed to the development and licensure of several vaccines internationally.</p>
	<p>Dr. Raches Ella <i>Head, Business Development and Advocacy, Bharat Biotech</i></p> <p>Dr. Ella is responsible for all interactions with local and supranational stakeholders to facilitate their implementation and operational uptake in the least developed countries. He evaluates opportunities including technologies and products ranging from preclinical-stage and clinical-stage candidate's opportunities and out-licensing. Additionally, partnering internal functions and external investigators. He holds a Medical Doctorate from Sri Ramachandra University.</p>
	<p>Mr. Weining Meng <i>Senior Director of Oversea Business, Sinovac.</i></p> <p>Mr. MENG Weining has more than 15 years of experience in vaccine regulatory affairs and business development. He leads the successful WHO prequalification projects in the company, and developed vaccine business in more than 40 countries. By promoting international cooperation, Sinovac provides vaccines to all over the world.</p>
	<p>Dr. Martin Reers <i>Technical Alliance & Partnership Coordinator, Biological E Ltd</i></p> <p>As an experienced vaccine technologist Dr Reers' role is implementing and managing international technical alliances / partnerships with Bio E. He spent more than 25 years in the vaccine field. Prior to his 11 years with Bio E he held several technical and managerial roles within Novartis. He received his PhD in Biochemistry from the University of Münster, Germany</p>

	<p>Dr. Mangesh Joshi <i>Alliance management and business development in SI IPL</i></p> <p>Biochemist with 22+ years of experience in process development for protein purification. He is also managing alliance management and business development in SI IPL.</p>
	<p>Mr. Nikhil Tamhankar <i>Alliance management and business development in SI IPL</i></p> <p>Pharmacist with 18+ years of experience in Business and Alliance Management in Life Science industry from discovery to development area.</p>
	<p>Mr. Taufik Wilmansyah <i>Head of Production Planning Department, Biofarma</i></p> <p>Mr. Taufik, MBA in operation with 14 years of experience in vaccine Industry. He is responsible for supply chain management with focus on efficiency for company.</p>
	<p>Ms. Li Meng <i>Director of International Cooperation, CNBG</i></p> <p>Her major duties encompass developing, managing and executing international cooperation projects with enterprises, NGOs, MNC partners and research organizations. With 15 years' working experiences, she specializes in corporate strategy and project management, business development and NGO relationships. She is the executive member of Emerging Biopharmaceutical Manufacturer Network, and served as the EC member of DCVMN from 2014-2016.</p>
	<p>Ms. Carmen Rodriguez <i>Scientist, Group Lead, Vaccines Assessment Prequalification Team, WHO</i></p> <p>Ms. Rodriguez has 29 years of experience in regulation of biologicals at the global level. She leads the Vaccines Assessment WHO Prequalification (PQ) team that evaluates vaccines and other biologicals submitted for PQ or risk/benefit assessment and post PQ monitoring activities to ensure their quality, safety and efficacy.</p>



Dr. Samvel Azatyan

Team Lead, Regulatory Convergence and Networks, WHO

Dr Azatyan is a Paediatrician with a PhD in clinical pharmacology and medical products regulation. Over his more than 20 years at WHO, he has had a wide range of leadership roles associated with the regulation of medical products, including supporting regulatory collaboration, convergence and harmonization, as well as regulatory capacity building and facilitation of products introduction in the countries.



Dr. Christina Von Hunolstein

Research Director and Coordinator of Bacterial Vaccine Section, Istituto Superiore di Sanità – Rome, Italy

Responsible for batch release of bacterial vaccines and for evaluation of the CTD, quality part of vaccine. She participated in EDQM and WHO collaborative studies for the establishment of alternatives to in vivo testing for potency of DT vaccines and currently co-leads a project on an alternative potency testing method for wP.



Mr. Patrick Tippoo

Head of Science and Innovation, Biovac, South Africa

Mr. Tippoo heads Science and Innovation at Biovac, in South Africa. He is a founding member and present Executive Director of the African Vaccine Manufacturing Initiative (AVMI) and currently serves as the Vice-President of DCVMN.